Cyprotex Highlights - January 2020
In December last year, our in-house expert on mitochondrial toxicity, Julie Eakins, presented a webinar entitled 'Utilising Early Mitochondrial Screens in Drug Safety'. The webinar covered topics such as the importance of mitochondrial toxicity identification early in the drug discovery process, the uses of in vitro screens to improve detection, and how to gain further insights into the mechanisms behind mitochondrial toxicity.
A recording of the webinar is now available to view online.
For questions and comments, please contact us on: enquiries@cyprotex.com.
Through the combined expertise of Cyprotex and our parent company Evotec, we have launched a new transcriptomics service which allows the entire transcriptome of the cell to be mapped using an untargeted RNA sequencing approach (RNA-seq).
The service will focus on in vitro toxicology where the transcriptomics approach allows adverse side effects to be detected at an earlier stage using highly sensitive mRNA markers and provides an improved mechanistic insight.
In March, Cyprotex and parent company Evotec will be exhibiting (booth #431 and #331) at the Annual Society of Toxicology Meeting (SOT), in Anaheim from March 15-19, 2020. At the event, toxicology expert and Cyprotex Director of US Scientific Operations, Dr Chris Strock, will be presenting a hosted session titled 'It's all in the Genes! Using Transcriptomics Combined with Cellular Imaging to Derisk DILI'. Find out more about this presentation and our other latest research being presented at SOT in the link below.
The very special GIANTmicrobes® mitochondria have landed and are beginning to make their way out into the wild. We’re excited to introduce our new friends to the rest of the world. To get your hands on one of our mitochondria, just place an order for one of our in vitro toxicology assays between the 1 Jan - 31 Mar 2020 inclusive, and quote the code MITO1.
Act fast, these little helpers are limited!
Read the latest news from parent company, Evotec:
- Further programme from endometriosis multi-target alliance between Evotec and Bayer advances into Phase I development.
- Second joint drug discovery programme announced between Evotec and Indivumed in the field of non-small cell lung cancer.
- Just - Evotec Biologics announces agreement with OncoResponse for cell line development, process development and manufacturing services.
- Just - Evotec Biologics initiates construction of late stage clinical and commercial manufacturing facility in North America using J.POD® technology.
- Multi-year collaboration with MSD announced for the production of biologics at future Just - Evotec Biologics J.POD® facility.
- New strategic alliance announced between Evotec and Bayer focusing on polycystic ovary syndrome.
- Evotec and Bristol-Myers Squibb expand human iPSC collaboration.
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
enquiries@cyprotex.com